why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: Tumor Mutational Burden Testing in Solid Tumors

CME Credits: 1.00

Released: 2023-10-26

A 58-year-old man with a history of type 2 diabetes, stage 3 chronic kidney disease, and JAK2-positive myeloproliferative neoplasm was referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. The patient was Black and of African descent. He agreed with the treatment recommendation of a gonadotropin-releasing hormone antagonist followed by antiandrogen therapy. This combination lowered his prostate-specific antigen (PSA) level from a peak of 55.18 ng/mL to 0.05 ng/mL (to convert to ?g/L, multiply by 1.0). The patient returned after 3 months to discuss genetic testing and options for further treatment, including radiation therapy, surgery, and a clinical trial. Molecular testing with a targeted next-generation sequencing (NGS) panel was ordered ().


Educational Objective
To understand how to interpret the results of diagnostic tests and apply them clinically.


View Full Course